Similar articles

• Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.

  Daugherty CK, Ratain MJ, Emanuel EJ, Farrell AT, Schilsky RL. Daugherty CK, et al. J Clin Oncol. 2008 Mar 10;26(8):1371-8. doi: 10.1200/JCO.2007.13.5335. Epub 2008 Jan 28. J Clin Oncol. 2008. PMID: 18227527 Review.
• Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

  Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS. Polman CH, et al. Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d. Neurology. 2008. PMID: 18362273
• Placebo: art or science?

  Rankin-Box D. Rankin-Box D. Complement Ther Clin Pract. 2008 Aug;14(3):149-51. doi: 10.1016/j.ctcp.2008.05.004. Complement Ther Clin Pract. 2008. PMID: 18640625 No abstract available.
• Clinical placebo interventions are unethical, unnecessary, and unprofessional.

  Hróbjartsson A. Hróbjartsson A. J Clin Ethics. 2008 Spring;19(1):66-9. J Clin Ethics. 2008. PMID: 18552056 No abstract available.
• The ethics of the placebo in clinical practice revisited.

  Louhiala P. Louhiala P. J Med Ethics. 2009 Jul;35(7):407-9. doi: 10.1136/jme.2008.028225. J Med Ethics. 2009. PMID: 19567687